Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Genelux CorporationNASDAQ: GNLX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.24M rose 11.6% year over year, ahead of the +3.6% change in trailing-twelve-month research & development. Sequentially, it fell 7.3% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.
Context
- Research & development amounted to 248137.5% of revenue in FY2025, up 10662.5 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of +3.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.85M USD
- Year-over-year change
- +4.5%
- 4-year CAGR
- +33.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.85M | +4.5% |
| FY2024 | 2024-12-31 | 19M | +48.8% |
| FY2023 | 2023-12-31 | 12.77M | +40.6% |
| FY2022 | 2022-12-31 | 9.08M | +43.7% |
| FY2021 | 2021-12-31 | 6.32M | — |
Research & Development vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.6% is the 5th highest of 10, against a peer median of -11.7%.
- Research & development amounts to 254962.5% of revenue for GNLX, versus a peer median of 3625.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M USD | -17.5% | +9.1% | — |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M USD | +11.3% | +45.0% | — |
| LTM Mar 2026 | $36.32M USD | +88.9% | +13.6% | — | |
| LTM Mar 2026 | $35.87M USD | +29.3% | +13.9% | — | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $20.4M USD | +3.6% | +29.8% | 254962.5% |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding GNLX) | — | -11.7% | +4.5% | 3625.8% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 11.07M | 170K | 8K | 8K |
| Cost of Revenue | 895K | 968K | 1.02M | 903K | 574K |
| Gross Profit | (895K) | 10.1M | (848K) | (895K) | (566K) |
| Gross Margin | — | 91.3% | -498.8% | -11187.5% | -7075.0% |
| Research & Development | 6.32M | 9.08M | 12.77M | 19M | 19.85M |
| Selling, General & Admin | 8.29M | 5M | 11.57M | 12.71M | 13.37M |
| Operating Expenses | 13.72M | 13.11M | 23.32M | 30.8M | 32.65M |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 574K |
| EBITDA | (13.67M) | (1.73M) | (26.46M) | (28.97M) | (31.57M) |
| EBITDA Margin | — | -15.6% | -15562.9% | -362075.0% | -394637.5% |
| Operating Income | (14.61M) | (3.01M) | (24.17M) | (31.7M) | (33.21M) |
| Operating Margin | — | -27.2% | -14214.7% | -396200.0% | -415175.0% |
| Interest Income | 0 | 0 | 244K | 1.46M | 1.07M |
| Interest Expense | 1.82M | 1.41M | 3.97M | 0 | 0 |
| Other Income / Expenses | (1.77M) | (1.09M) | (4.13M) | 1.83M | 1.07M |
| Income Before Tax | (16.38M) | (4.11M) | (28.3M) | (29.87M) | (32.15M) |
| Pre-Tax Margin | — | -37.1% | -16645.3% | -373362.5% | -401812.5% |
| Income Tax Expense | 0 | 1.1M | 0 | 0 | 0 |
| Net Income | (17.8M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Net Margin | — | -47.0% | -16645.3% | -373362.5% | -401812.5% |
| EPS (Basic) | (0.69) | (0.21) | (1.16) | (0.95) | (0.86) |
| EPS (Diluted) | (0.69) | (0.21) | (1.16) | (0.95) | (0.86) |
| Weighted Avg Shares | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M |
| Weighted Avg Shares (Diluted) | 23.62M | 24.55M | 24.43M | 31.45M | 37.18M |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.